Mosedipimod is under clinical development by Enzychem Lifesciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Mosedipimod’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Oral Mucositis took place on 11 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mosedipimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Mosedipimod overview

Mosedipimod (EC-18) is under development for the treatment of acute radiation syndrome, sepsis, rheumatoid arthritis, asthma, nonalcoholic steatohepatitis, liver fibrosis, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, mustard gas (sulfur mustard) poisoning, chemotherapy induced oral mucositis and coronavirus disease 2019 (Covid-19) pneumonia, coronavirus disease 2019 (Covid-19) associated acute respiratory distress syndrome. It is administered through oral route as capsule. The drug candidate is a monoacetyldiacylglyceride derived from deer antlers. It is developed based on lipid medicine platform technology. The drug candidate was also under development for the treatment of biliary cancer. It was also under development for chemotherapy induced neutropenia (CIN) including febrile and afebrile neutropenia

Enzychem Lifesciences overview

Enzychem Lifesciences (Enzychem) is a Pharmaceutical company. It develops and produces novel drugs and active pharmaceutical ingredients (APIs). It is developing new drugs to treat diseases like asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, acute radiation syndrome, sepsis, and autoimmune disorders. EC-18 is the company’s pipeline product which treats the cancer and inflammationEnzychem servers the patients across the globe. It has research and development center in Chungcheongbuk-do, South Korea. The company has its operations in South korea and the USA. The company is headquartered in Seocho-gu, Seoul, South Korea.

Quick View Mosedipimod LOA Data

Report Segments
  • Innovator
Drug Name
  • Mosedipimod
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
  • Respiratory
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.